US FDA Biologic Transition Plan Creates 'Dead Zone' For Applications, Sponsors Fear
This article was originally published in SRA
Executive Summary
The way in which the US Food and Drug Administration is planning to interpret the Biologics Price Competition and Innovation Act's 'transition provisions' for certain protein products would create a 'dead zone' or 'blackout' period for new applications that could last several years, industry stakeholders warn.